2-Methyl-thiazol-carbnonsaeure-(5)-anilid | 91137-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-thiazol-carbnonsaeure-(5)-anilid
• 英文别名: 2-methyl-thiazole-5-carboxylic acid anilide；2-methyl-N-phenyl-1,3-thiazole-5-carboxamide
• CAS: 91137-85-8
• 化学式: C₁₁H₁₀N₂OS
• 分子量: 218.279
• InChiKey: LVHNQBOPEZCUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基噻唑-5-甲酸 、 苯胺 在 三氯氧磷 作用下， 生成 2-Methyl-thiazol-carbnonsaeure-(5)-anilid
  参考文献：
  名称：

  Lebedeva,I.V. et al., Journal of general chemistry of the USSR, 1961, vol. 31, p. 2444 - 2448

  摘要：

  DOI：

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2017015451A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式（I），或其药用可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物能够抑制由乙型肝炎病毒（HBV）编码的蛋白质，或干扰乙型肝炎病毒的生命周期功能，同时也可作为抗病毒药物使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170022150A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A 1 -Y-A 2 -Z-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的化学式（I），或其药学上可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于给患有HBV感染的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140206691A1

  公开（公告）日：2014-07-24

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐，含有这种化合物的药物组合物，以及使用这种化合物治疗蛋白酪氨酸激酶相关疾病（如免疫和肿瘤疾病）的方法。
• PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS
  申请人：Chen Bang-Chi

  公开号：US20090149650A1

  公开（公告）日：2009-06-11

  The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R 2 , R 3 , R 4 , and R 5 , are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.

  本发明涉及制备具有以下公式及其结晶形式的化合物的方法，其中Ar是芳基或杂环芳基，L是可选的烷基链，R2、R3、R4和R5如本说明书中所定义的，这些化合物可用作激酶抑制剂，特别是蛋白酪氨酸激酶和p38激酶的抑制剂。
• ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2078003B1

  公开（公告）日：2017-03-08